Trial reportJournal of the American Geriatrics Society2017
Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance.
Trial report in Journal of the American Geriatrics Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome.JAMA network open · 2022Trial
- The prevalence and related factors of metabolic syndrome in outpatients with first-episode drug-naive major depression comorbid with anxiety.Scientific reports · 2021Trial
- Trial
- Sodium-Glucose Cotransporter-2 Inhibitors in Mood Disorders: A Narrative Review of Mechanisms, Evidence, and Challenges.Neuropsychiatric disease and treatment · 2026Review
- Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use.Translational psychiatry · 2025Article
- Article
- Brain inflammaging in the pathogenesis of late-life depression.Human cell · 2024Review
- Prevalence and clinical correlates of abnormal lipid metabolism in older Chinese patients with first-episode drug-naïve major depressive disorder.BMC psychiatry · 2024Article
- Association of subclinical hypothyroidism with metabolic syndrome and its components among outpatients with first-episode drug-naïve major depressive disorder: a large-scale cross-sectional study.European archives of psychiatry and clinical neuroscience · 2024Article
- Incidence and risk factors of depression in patients with metabolic syndrome.World journal of psychiatry · 2024Article
- Effects of Metabolic Syndrome and Sex on Stress Coping Strategies in Individuals with Depressive Disorder.Metabolites · 2023Article
- Plasminogen Activator Inhibitor-1: Potential Inflammatory Marker in Late-life Depression.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Article
- Article
- Early-onset late-life depression: Association with body mass index, obesity, and treatment response.Comprehensive psychoneuroendocrinology · 2021Article
- How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Brain and behavior · 2021Article
- Associations between testosterone and metabolic syndrome in depressed and non-depressed older men and women.International journal of geriatric psychiatry · 2019Article
- Suffering from Cerebral Small Vessel Disease with and without Metabolic Syndrome.Open medicine (Warsaw, Poland) · 2019Article
- Insights into Macrophage Heterogeneity and Cytokine-Induced Neuroinflammation in Major Depressive Disorder.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND/
objectivesMetabolic syndrome (MetS) is the co-occurrence of obesity and metabolic derangements. Prior research implicates MetS in prolongation of the course of depression in older adults, but its effect on antidepressant response is unknown in this population. The objective was to determine whether MetS and related metabolic dyscrasias are associated with decreased rate of remission from depression in older adults treated pharmacologically for depression.
designSecondary analysis of a randomized controlled trial.
settingThree academic medical centers in North America.
participantsAdults aged 60 and older (mean age 69.1) with major depressive disorder (MDD) (N = 435).
interventionOpen-label, protocolized treatment with extended-release venlafaxine for 12 or more weeks. MEASUREMENTS: Time to remission from depression, with remission defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 10 or less at last two visits.
resultsTwo hundred twenty-two participants (51%) met criteria for MetS at baseline; MetS was associated with greater severity (MADRS score) and chronicity of depression at baseline. Remission was achieved in 182 participants (42%). In the unadjusted analysis, MetS was associated with prolonged time to remission (hazard ratio for remission = 0.71, 95% confidence interval = 0.52-0.95), but this relationship was not significant in the adjusted model; greater number of MetS components and lower high-density lipoprotein cholesterol had similar effects. Only diastolic blood pressure (DBP) was a significant predictor of time to remission before and after adjustment, with higher DBP predicting longer time to remission. Insulin sensitivity did not predict time to remission.
conclusionThe presence of MetS in older adults with depression was associated with greater symptom severity and chronicity of depression, which appears to have accounted for the poorer antidepressant response observed in those with MetS. Additionally, our preliminary finding of an association between higher DBP and poorer antidepressant response bears further examination and replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.